A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) (SAkuraSun)
A Phase III, Multicenter, Open-Label, Uncontrolled Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Reference Study ID Number: WN41733 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728 (U.S.)
- E-post: global-roche-genentech-trials@gene.com
Studera Kontakt Backup
- Namn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
- E-post: global.medical_information@roche.com
Studieorter
-
-
-
Ciudad Autonoma Buenos Aires, Argentina, C1249ABN
- Rekrytering
- Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan
-
Córdoba, Argentina, X5004FHP
- Rekrytering
- Clinica Universitaria Reina Fabiola
-
-
-
-
Val-de-Marne
-
Le Kremlin-Bicêtre, Val-de-Marne, Frankrike, 94275
- Rekrytering
- Centre Hospitalier Universitaire de Bicêtre
-
-
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80218-1007
- Rekrytering
- Children's Hospital Colorado.
-
-
-
-
Lazio
-
Rome, Lazio, Italien, 00165
- Rekrytering
- IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN
-
-
Lombardy
-
Pavia, Lombardy, Italien, 27100
- Rekrytering
- Fondazione Istituto Neurologico Mondino IRCCS
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510120
- Rekrytering
- Guangzhou Women and Children's Medical Center
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 201102
- Rekrytering
- Children's Hospital of Fudan University
-
-
-
-
Mexico CITY (federal District)
-
DF, Mexico CITY (federal District), Mexiko
- Rekrytering
- Grupo Medico Camino
-
Mexico City, Mexico CITY (federal District), Mexiko, 06720
- Rekrytering
- Hospital Infantil de Mexico Federico Gomez
-
-
-
-
-
Gdansk, Polen, 80-214
- Aktiv, inte rekryterande
- Uniwersyteckie Centrum Kliniczne
-
Warsaw, Polen, 04-730
- Rekrytering
- Instytut "Pomnik - Centrum Zdrowia Dziecka"
-
-
-
-
-
London, Storbritannien, WC1N 3JH
- Rekrytering
- Great Ormond Street Hospital for Children
-
-
-
-
-
Kocaeli, Turkiet (Türkiye), 6810
- Rekrytering
- Kocaeli University Research and Application Hospit
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Age at screening 2-11 years, inclusive
-
Body weight at screening >=10 kg
-
For female patients of childbearing potential (postmenarchal): agreement to either remain completely abstinent (refrain from heterosexual intercourse) or to use a reliable means of contraception
-
Diagnosed as having NMOSD with AQP4 antibody seropositive status as defined by the Wingerchuk 2015 criteria Clinical evidence of at least one documented attack (including first attack) in the last year prior to screening:
- Documented history of a positive anti-AQP4 antibody test or a positive anti-AQP4 antibody test at screening;
-
Neurological stability for >=30 days prior to baseline
-
Expanded Disability Status Scale (EDSS) 0 to 6.5
-
For participants receiving a baseline immunosuppressant treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline
Exclusion Criteria:
- Pregnancy or lactation
- Evidence of other demyelinating disease mimicking NMOSD
- Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline
- Evidence of chronic active hepatitis B or C
- Evidence of untreated latent or active tuberculosis (TB)
- Receipt of a live or live-attenuated vaccine within 6 weeks prior to baseline
- History of severe allergic reaction to a biologic agent
- IVIg or subcutaneous Ig (SCIg) within 4 weeks prior to enrollment/Day 1
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Cohort 1: Participants with body weight ≥10kg to <20kg
Satralizumab will be administered SC Q6W in a cohort of at least 2 evaluable patients |
Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period. |
|
Experimentell: Cohort 2 Participants with body weight ≥20kg to <40kg
Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter. |
Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period. |
|
Experimentell: Cohort 3 Participants with body weight ≥40kg
Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter. |
Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Summary of Observed Serum Concentration of Satralizumab
Tidsram: Week 48
|
Week 48
|
|
Apparent Clearance [CL/F] of Satralizumab
Tidsram: Week 48
|
Week 48
|
|
Apparent Volume of Distribution [V/F] of Satralizumab
Tidsram: Week 48
|
Week 48
|
|
Area Under the Concentration-time Curve [AUC] of Satralizumab
Tidsram: Week 48
|
Week 48
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Förändring från baslinjen i Expanded Disability Status Scale (EDSS) vid vecka 24 och 48
Tidsram: Baslinje, vecka 24, vecka 48
|
Baslinje, vecka 24, vecka 48
|
|
Proportion of Relapse-free Participants by Week 48
Tidsram: Week 48
|
Week 48
|
|
Annualized Relapse Rate (ARR), defined as the average number of relapses for each year of the study
Tidsram: Week 48
|
Week 48
|
|
Time to First Relapse (TFR) after enrollment, defined as the time from enrollment until the first occurrence of relapse, as determined by the investigator
Tidsram: Week 48
|
Week 48
|
|
Time to Relapse Requiring Rescue Therapy
Tidsram: Week 48
|
Week 48
|
|
Change from Baseline in Visual Acuity at Weeks 24 and 48
Tidsram: Baseline, Week 24, Week 48
|
Baseline, Week 24, Week 48
|
|
Change from Baseline in FACES Pain Rating Scale at Weeks 24 and 48
Tidsram: Baseline, Week 24, Week 48
|
Baseline, Week 24, Week 48
|
|
Change from Baseline in EuroQol 5-Dimension, Youth (EQ-5D-Y) Score and its Proxy at Weeks 24 and 48
Tidsram: Baseline, Week 24, Week 48
|
Baseline, Week 24, Week 48
|
|
Incidence and Severity of Adverse Events
Tidsram: Week 48
|
Week 48
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Trials, Hoffmann-La Roche
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- WN41733
- 2019-004092-39 (EudraCT-nummer)
- 2023-507817-85-00 (Ctis)
- 2023 (U.S.S. NIH-anslag/kontrakt)
- 2019 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .